𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Elicitation of a Beta Prior for Bayesian Inference in Clinical Trials

✍ Scribed by Yujun Wu; Weichung J. Shih; Dirk F. Moore

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
175 KB
Volume
50
Category
Article
ISSN
0323-3847

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Some extensions and applications of a Ba
Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials
✍ Peter F. Thall; Hsi-Guang Sung πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

We present some practical extensions and applications of a strategy proposed by Thall, Simon and Estey for designing and monitoring single-arm clinical trials with multiple outcomes. We show by application how the strategy may be applied to construct designs for phase IIA activity trials and phase I

A Bayesian hierarchical survival model f
A Bayesian hierarchical survival model for the institutional effects in a multi-centre cancer clinical trial
✍ Yutaka Matsuyama; Junichi Sakamoto; Yasuo Ohashi πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 159 KB πŸ‘ 2 views

In randomized clinical trials comparing treatment effects on diseases such as cancer, a multi-centre trial is usually conducted to accrue the required number of patients in a reasonable period of time. While we interpret the average treatment effect, it is necessary to examine the homogeneity of the

Inference for a RPW-Type Clinical Trial
Inference for a RPW-Type Clinical Trial with Repeated Monitoring for the Treatment of Rheumatoid Arthritis
✍ Atanu Biswas; Anup Dewanji πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 1 views

## Abstract The present paper describes a controlled clinical trial to investigate the effect of Pulsed Electro‐Magnetic Field for the treatment of sequentially entering patients with Rheumatoid Arthritis. According to the study design, repeated monitorings of the patients are carried out to assess

A trial of razoxane (ICRF-159) in patien
A trial of razoxane (ICRF-159) in patients with prior therapy for Modgkin's Lymphoma
✍ Michael P. Corder; David B. McFadden; Shirley J. Bell πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 232 KB πŸ‘ 1 views

Razoxane (ICRF-159) was administered to 11 patients with Stage IV nodular sclerosing Hodgkin's lymphoma. A weekly schedule was employed with a starting dose of 1000 mg/m2 in divided doses. The dose was escalated up to 2000 mg/m2 weekly as tolerated. One objective partial remission was observed. The